Skip to main content
Premium Trial:

Request an Annual Quote

Nazem & Co., Zymark and Waters, SBI, Amresco


Nazem & Co to Launch Proteomics VC Fund

Venture capital firm Nazem & Co. said last week that it plans to launch a $150 million fund devoted to proteomics companies in the Northeast.

Fred Nazem, a managing partner in the New York City-based firm, said the fund should close by late January, but was reluctant to specify what types of proteomics companies the fund would seek to support. “We can’t accommodate every company,” he said, “and I don’t want to look like I’m getting ahead of myself.”

Nazem’s venture capital portfolio includes companies such as Genetix Pharmaceuticals, a developer of gene therapies for treating cancer, and SiRF Technology, which is developing consumer applications for GPS and other wireless technologies.


Zymark and Waters to Develop HPLC Software

Zymark and Waters have agreed to jointly develop mutually compatible software for automated high-performance liquid chromatography (HPLC) systems, the companies said last week.

As a member of Waters’ Software Partners Program, Zymark will collaborate with Waters to design software that will allow its Prelude automated liquid handling workstation to function seamlessly with Waters’ Millennium chromatography software.

Zymark, based in Hopkinton, Mass., develops robotics and liquid handling workstations, as well as scheduling and data management software. It is the first collaboration between Zymark and Milford, Mass.-based Waters, a manufacturer of chromatography separation systems.


Former NABI Exec Joins SBI As President and COO

David Muth has joined Structural Bioinformatics (SBI) as president and chief operating officer, the company said last week.

In his new role, Muth will oversee company operations such as sales, marketing, and database production, as well as drug research and development at SBI and its European subsidiary, SBI-Advanced Technologies.

Muth formerly served as senior vice president of business operations for pharmaceutical company NABI, where he helped transform the company from a plasma supplier into an integrated biopharmaceutical company, SBI said. Prior to NABI, Muth held a variety of senior management roles at Johnson & Johnson, where he helped launch antifungal and contraceptive pharmaceuticals that garnered hundreds of millions of dollars in sales.


Amresco Launches Pre-Cast Second Dimension Mini-Gels

Solon, Ohio-based Amresco has released its pre-cast second dimension gels, known as 2D RITE-Gels, the company said last week.

The tris-glycine gradient mini-gels contain a 1 cm, 4 percent gradient, and a molecular weight reference lane. The gels are manufactured as pre-poured glass cassettes with 1 mm thickness, and have dimensions of 10 cm by 10 cm.

The product line has separation ranges of 6-240 kD, a shelf life of 4 months, and gradient formats of 8-16 percent and 10-20 percent. A box contains 5 gels.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.